WallStSmart
YDES

YD Bio Ltd

NASDAQ: YDES · HEALTHCARE · BIOTECHNOLOGY

$5.19
-4.29% today

Updated 2026-06-05

Market cap
$171.41M
P/E ratio
P/S ratio
335.86x
EPS (TTM)
$-0.12
Dividend yield
52W range
$2 – $25
Volume
0.0M

YD Bio Ltd (YDES) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item202020212022202320242025
Total assets$117.59M$118.06M$17.93M$321212.00$6.86M$13.78M
Cash & equivalents$693818.00$5403.00$14129.00$87098.00$3.13M$6.01M
Current assets$830767.00$129560.00$202705.00$271724.00$3.47M$9.67M
Total liabilities$17.81M$9.11M$6.74M$298218.00$273980.00$16.64M
Current liabilities$302219.00$2.00M$5.55M$298218.00$263060.00$1.64M
Long-term debt
Shareholder equity$99.78M$108.96M$11.20M$22994.00$6.59M$-2.86M
Retained earnings$-15.22M$-6.52M$-6.53M$-515484.00$-1.93M$-10.24M
Accounts receivable$18073.00$98434.00$262796.00$712263.00
Inventory$69404.00$37335.00$1.88M
Goodwill

Frequently asked questions

What is YD Bio Ltd's revenue?

YD Bio Ltd's trailing twelve-month revenue is $510360.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is YDES?

In its most recent fiscal year, YDES ran a gross margin of -7.06%, an operating margin of -883.31%, and a net margin of -1,392.61%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does YDES generate?

YDES produced $-8.04M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is YDES's balance sheet healthy?

YDES holds $6.01M in cash and equivalents against — in long-term debt, on $-2.86M of shareholder equity. That debt is best read against the cash flow the business throws off each year.